Final ACTT-1: Remdesivir Results

The drug reduced time to recovery among hospitalized patients with COVID-19 who had lower respiratory tract infection.

In May 2020, preliminary results of the National Institutes of Health–sponsored Adaptive COVID-19 Treatment Trial (ACTT-1) were published (NEJM JW Infect Dis Aug 2020 and N Engl J Med 2020 May 22; [e-pub]). At that time, not all participants had finished the trial. Now the final results after complete follow-up are published.

ACTT-1 randomized 1062 hospitalized patients with COVID-19 and lower respiratory tract infection to receive 10 days of intravenous remdesivir or placebo. The main results were the following:

The remdesivir group had a shorter median time to recovery than the placebo group: 10 versus 15 days.
The mortality estimate by day 29 was 11.4% with remdesivir and 15.2% with placebo (hazard ratio, 0.73; 95% confidence interval, 0.52…

Reviewing Author

Rajesh T. Gandhi, MD

Disclosures

Grant/Research SupportNIH

Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)

Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)